AGEN : Summary for Agenus Inc. - Yahoo Finance

Canadian Markets close in 4 hrs 7 mins

Agenus Inc. (AGEN)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.71-0.06 (-1.59%)
As of 11:53AM EST. Market open.
People also watch
CTICARRYCRISARIAEXEL
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.77
Open3.77
Bid3.73 x 2200
Ask3.74 x 2000
Day's Range3.71 - 3.82
52 Week Range2.61 - 7.49
Volume281,849
Avg. Volume1,260,419
Market Cap323.25M
Beta2.85
PE Ratio (TTM)-2.75
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Agenus Inc (AGEN) Incorporates NCI In Evaluation Of Prophage-Keytruda Combo
    Insider Monkey4 days ago

    Agenus Inc (AGEN) Incorporates NCI In Evaluation Of Prophage-Keytruda Combo

    Having agreed on a collaborative deal, Agenus Inc (NASDAQ:AGEN) and National Cancer Institute (NCI) will work together in evaluating Agenus’ personalized autologous vaccine candidate, Prophage (HSPPC-96). MRK PD-1 therapy, Keytruda from Merck & Co., Inc.(NYSE:MRK) will also be incorporated. Merck’s inclusion comes on the back of its incredible performance in the past year having recorded […]

  • Investopedia5 days ago

    Clinical Trial Hopes Drugs Help Body Fight Cancer

    Agenus will begin a study that pairs a personalized cancer vaccine with Merck's PD-1 pathway blocker.

  • Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo
    Zacks5 days ago

    Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo

    Agenus (AGEN) entered into a clinical trial collaboration with the National Cancer Institute to evaluate Prophage, in conjunction with Merck's (MRK) Keytruda.